Farsta, Sweden

Barbro K Goransson-Dahlander

This inventor holds 1 USPTO granted patent. Top assignee: Ab Kabi. Active years: 1979.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 1979

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Barbro K Goransson-Dahlander: Innovator in Pharmacodynamics

Introduction

Barbro K Goransson-Dahlander is a notable inventor based in Farsta, Sweden. She has made significant contributions to the field of pharmacodynamics, particularly through her innovative work on indan derivatives. Her research has led to the development of new pharmacodynamically active compounds that hold promise for various applications in medicine.

Latest Patents

Barbro holds a patent for "Pharmacodynamically active indan derivatives." This invention relates to new pharmacodynamically active compounds characterized by a specific general structure. The compounds include amine oxides, quaternary ammonium compounds, and salts with physiologically acceptable acids. The patent outlines the structural components of these compounds, including various alkyl and halogen radicals, which contribute to their pharmacological properties.

Career Highlights

Throughout her career, Barbro has demonstrated a commitment to advancing pharmaceutical science. Her work has not only resulted in a patent but has also contributed to the broader understanding of pharmacodynamics. She is associated with Ab Kabi, a company that focuses on innovative pharmaceutical solutions.

Collaborations

Barbro has collaborated with esteemed colleagues such as Nils A Jonsson and Ferenc Merenyi. These partnerships have enriched her research and contributed to the successful development of her patented compounds.

Conclusion

Barbro K Goransson-Dahlander is a pioneering inventor whose work in pharmacodynamics has the potential to impact the medical field significantly. Her innovative compounds and collaborations highlight her dedication to advancing pharmaceutical research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…